Skip to Main Content

Paper Details

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
RMD Open
1
2023
Author NameAffiliation
Dafna D GladmanToronto Western Hospital, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute
  • 1 - 1

Datasets

Release 1.2